Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C round, bringing the total raised to €344 million (US $401 million). The financing will support the advancement of its lead antibody-drug conjugate (ADC) programme and the company’s proprietary ADC platform technologies, enabling expansion into new solid-tumour indications and earlier treatment lines.
Science Significance
The funding will accelerate development of Tubulis’s lead candidate TUB-040, an ADC targeting the NaPi2b antigen in platinum-resistant high-grade serous ovarian cancer, following positive early clinical proof-of-concept data. Tubulis’s platform leverages a unique “matched” ADC design that optimises biophysical properties, enhances on-tumour delivery, and expands therapeutic windows, representing a scientific advance in precision oncology and ADC engineering. The ability to scale this platform technology across multiple tumour antigens underscores the broader scientific potential for next-generation ADCs.
Regulatory Significance
With the company moving rapidly toward pivotal clinical trials, the robust Series C backing strengthens Tubulis’s regulatory readiness—supporting GMP manufacturing scale-up, compliance with international cGxP standards, and readiness for regulatory filings in oncology indications. The data used to justify the financing includes early clinical read-outs presented at major oncology conferences, indicating that Tubulis is positioning itself for accelerated regulatory pathways such as Breakthrough Therapy Designation or Fast Track status, particularly in unmet oncology indications.
Advertisement
Business Significance
From a commercial perspective, the €344 million raise is a landmark financing event for a private ADC-developer, signalling investor confidence in Tubulis’s strategy and technology. The expanded investor syndicate—including Fidelity, Janus Henderson, Blackstone Multi-Asset Investing and existing backers like Venrock Healthcare—provides both financial strength and strategic credibility. This capital infusion enables Tubulis to de-risk its pipeline, expand global operations, and negotiate potential partnerships or licensing deals with larger pharmaceutical companies seeking differentiated ADC assets.
Patients’ Significance
For patients facing solid tumours such as platinum-resistant ovarian cancer or lung adenocarcinoma, the acceleration of Tubulis’s TUB-040 and pipeline programmes offers hope for new treatment options where few exist. By advancing a modality that promises improved targeting, safety and efficacy, Tubulis aims to deliver clinical benefit—reduced off-tumour toxicity, enhanced efficacy and earlier access to therapy—which could translate into improved outcomes and survival for patients in high-unmet-need settings.
Policy Significance
The size and nature of this financing reflect broader policy and investment trends that support innovation in oncology and precision medicine, especially for biologics and ADC platforms. Governments and regulatory bodies are increasingly emphasising incentives for high-impact therapies, rapid development, and global collaboration—particularly where patient need is urgent. The transaction underscores the role of venture capital and private funding in complementing public-health policy goals around accelerating access to novel cancer therapies and maintaining global competitiveness in biotech innovation.
In summary, Tubulis’s €344 million Series C closing marks a major milestone in biopharmaceutical innovation, combining scientific depth, regulatory momentum, business strategy and patient-impact potential. As the company advances TUB-040 into pivotal trials and expands its ADC platform, it stands at the forefront of the next generation of cancer therapies. For stakeholders in the life-sciences ecosystem, this development highlights how rigorous science, substantial capital and compliance with cGxP standards converge to drive transformative drug development.
Source: Tubulis. press release
